# Niagen Bioscience, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Niagen Bioscience, Inc.). ## Overview Niagen Bioscience, Inc. develops and commercializes Niagen-branded nicotinamide riboside products across consumer supplements, ingredient supply, and pharmaceutical applications. The company operates through consumer products, ingredients, and pharmaceutical-oriented research activities, with sales in the United States and select international markets. ## Products & services • Tru Niagen® consumer dietary supplements • Food-grade Niagen® ingredient supply • Pharmaceutical-grade Niagen® for compounding • NAD+ test kits for healthcare practitioners • Research and development services for phytochemicals - **Consumer Products** (75%) — Finished dietary supplement products sold under the Tru Niagen® brand and related practitioner-facing test kits. - **Ingredients** (22%) — Food-grade and pharmaceutical-grade Niagen® ingredients sold to manufacturers, outsourcing facilities, and compounding pharmacies. - **Analytical Reference Standards and Services** (3%) — Natural product fine chemicals and related research services historically sold to technical and research customers. - **Pharmaceutical Segment** (0%) — Research and development of a therapeutic candidate for rare advanced aging diseases, without commercial sales. - Tru Niagen® consumer dietary supplements - Food-grade Niagen® ingredient supply - Pharmaceutical-grade Niagen® for compounding - NAD+ test kits for healthcare practitioners - Research and development services for phytochemicals ## Customers The company sells to consumers seeking NAD+ and healthy-aging supplements, primarily through Tru Niagen® and related direct-to-consumer channels. It also sells to commercial partners, manufacturers, FDA-registered 503B outsourcing facilities, and compounding pharmacies that use Niagen ingredients in finished products or compounded formulations. A smaller portion of activity serves technical and research customers that need analytical standards, phytochemicals, or related services. - **Direct-to-consumer supplement buyers** (primary) — Consumers purchase Tru Niagen® through the company’s e-commerce channels for daily supplementation and healthy-aging use. - **Distribution and retail partners** (primary) — Authorized resellers, marketplaces, and specialty retail partners buy finished products for broader consumer reach. - **Ingredient manufacturers** (primary) — Consumer-product manufacturers buy food-grade Niagen® as an input for dietary supplement and food formulations. - **503B outsourcing facilities and compounding pharmacies** (secondary) — These customers buy pharmaceutical-grade Niagen® for compounding under applicable regulatory requirements. - **Healthcare practitioners** (secondary) — Practitioners buy NAD+ test kits and may also support patient access to Niagen Plus-related offerings. - **Research and technical customers** (emerging) — Scientific and laboratory customers buy analytical reference standards and related research services. - Consumers buying Tru Niagen® for healthy-aging supplementation - E-commerce shoppers purchasing directly through TruNiagen.com - Distributors and authorized resellers expanding retail reach - Manufacturers using food-grade Niagen® in finished products - 503B outsourcing facilities and compounding pharmacies using pharma-grade Niagen® - Healthcare practitioners buying NAD+ test kits and supporting products ## Geography The company is headquartered in the United States and generates most of its business there, especially through direct e-commerce, distributors, and ingredient customers. It also sells into select international markets across Asia-Pacific, Europe, the Middle East, and North America, with distribution expanding through regional partners and global e-commerce platforms. Geography matters because product claims, compounding, and ingredient sales are subject to local regulatory requirements and partner availability. - United States is the core market for consumer and ingredient sales - Canada is served through direct-to-consumer e-commerce - Select Asia-Pacific markets support international consumer distribution - Europe and the Middle East are served through regional partners - International sales depend on local regulatory feasibility and partner networks ## Strategy The company’s strategy centers on expanding Tru Niagen® consumer demand while deepening ingredient adoption with commercial partners and regulated compounding channels. It also uses scientific positioning, regulatory support, and intellectual property protection to differentiate Niagen® as a branded ingredient platform. Longer term, the company is building a pharmaceutical pipeline around its patent portfolio and rare advanced aging disease candidate. - **Scale consumer brand demand** (short-term) — Tru Niagen® is the main commercial engine and supports repeat purchases and brand equity. - **Broaden ingredient commercialization** (medium-term) — Ingredient sales diversify the business and leverage the same core Niagen technology across multiple end markets. - **Expand international reach** (medium-term) — International partners increase addressable market size without building a full direct sales force in every country. - **Advance pharmaceutical development** (long-term) — A successful therapeutic program could create a higher-value, patent-protected revenue stream. - Grow Tru Niagen® awareness through digital and direct-to-consumer marketing - Expand ingredient adoption with manufacturers and outsourcing facilities - Support partners with technical, regulatory, and supply-chain assistance - Extend international distribution through strategic partners and e-commerce - Develop a pharmaceutical candidate using the Niagen patent portfolio ## Risks The business depends heavily on consumer acceptance of Tru Niagen® and on maintaining effective marketing, distribution, and partner relationships. It also faces regulatory, reputational, and competitive risks because its products operate in wellness, dietary supplement, and compounding channels that are sensitive to claims, compliance, and public perception. Pharmaceutical development adds clinical, regulatory, and intellectual property risk, while the company’s international footprint introduces local-market and partner execution risk. - **Dependence on Tru Niagen® consumer sales** [high] — A large share of revenue is tied to one branded product family, so demand softness would affect the whole business. - **Regulatory and compliance risk** [high] — Dietary supplements, ingredient claims, and compounding activities are subject to FDA, FTC, and local rules. - **Third-party clinic and partner reputation risk** [medium] — The brand can be affected by conduct at clinics or by resellers even when the company does not control operations. - **Competitive pressure** [medium] — Larger wellness and ingredient companies may outspend the company on marketing, distribution, and product development. - **Pharmaceutical development uncertainty** [high] — Drug development requires successful R&D, regulatory approval, and patent protection before commercialization. - Heavy dependence on Tru Niagen® sales and consumer demand - Regulatory scrutiny of supplement, advertising, and compounding claims - Brand damage from clinic-level issues or misleading third-party marketing - Competition from larger wellness and ingredient companies - Need to maintain distributor and partner relationships across markets - Clinical and IP risk in pharmaceutical development ## Accounting Revenue recognition is important because the company sells through direct e-commerce, distributors, ingredient partners, and regulated facilities, each of which can have different timing, returns, and discount patterns. Investors should also watch estimates around deferred revenue, returns, and any valuation or impairment judgments tied to patents and other intangibles. Because the company has used stock-based compensation, repurchases, and prior financing activities, equity-related accounting and noncash items can also affect comparability. - **Revenue recognition under ASC 606** — Affects net sales timing and comparability across quarters - **Deferred revenue and reserves** — Can change reported revenue and liabilities - **Intangible assets and patent-related amortization** — Affects operating expense and asset carrying values - **Stock-based compensation** — Affects operating expense, equity, and cash flow presentation - Revenue timing differs across e-commerce, distributors, and ingredient partners - Returns and discounts affect reported net sales - Deferred revenue estimates can shift period-to-period results - Patent and intangible asset lives affect amortization expense - Stock-based compensation and option exercises affect equity and cash flow --- *Last updated: 2026-04-29T04:41:49.663875+00:00*